STK36: a potential prognostic biomarker in hepatocellular carcinoma
4 affiliations
- 1Department of Pathology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang District, Beijing, 100015 China
- 2Department of Neurosurgery, the Fourth Medical Center of PLA General Hospital, Beijing, China
- 3Department of Cardiovascular Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang District, Beijing, 100015 China
- 4Department of Pathology, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000 China
Abstract
Background: STK36, a member of the serine/threonine kinase family, has been reported to be highly expressed in cancers. However, there have been fewer reports on the expression and role of STK36 in hepatocellular carcinoma (HCC).
Methods: We used the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases to evaluate the differential expression of STK36 in HCC and normal tissues. Immunohistochemistry (IHC) and quantitative real-time reverse transcription polymerase chain reaction(qRT-PCR) validated the expression of STK36 in HCC. The chi-square test was employed to study the relationship between STK36 and clinical characteristics. The prognostic significance of STK36 expression was analyzed using Kaplan-Meier and Cox regression methods. We also studied the association between STK36 and immunity. We discussed STK36 expression at the single-cell and spatial transcriptome distribution levels. Drug sensitivity analysis was utilized to discuss the link between STK36 expression and small-molecule drugs. Gene Set Enrichment Analysis (GSEA) was used to discuss the function of STK36 in HCC.
Results: STK36 expression was elevated in HCC from the TCGA and ICGC databases. IHC and qRT-PCR confirmed the overexpression of STK36 in HCC. STK36 expression had a positive correlation with T stage (tumor stage). STK36 expression was an independent prognostic factor affecting HCC patients’ outcomes. A relationship existed between STK36 expression and the infiltration of immune cells as well as immune checkpoints. Single-cell and spatial transcriptome analyses demonstrated that STK36 was upregulated in HCC. GSEA showed that STK36 was involved in some pathways, including ECM-receptor interaction, cell cycle, etc.
Conclusion: STK36 acts as a potential prognostic index in HCC, serves as a potential biomarker for predicting response to immunotherapy, and provides a rationale for further functional studies.
Related
- Interleukin-6 as a prognostic biomarker in hepatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis
- BRIX1 Promotes Hepatocellular Carcinoma Progression via the MAPK/ERK Pathway and Serves as a Prognostic Biomarker
- Pan-cancer analysis identifies ANGPT4 as a potential prognostic biomarker associated with the tumor microenvironment in kidney renal clear cell carcinoma
- The ferroptosis-related LncRNA CASC9 reveals its potential as a diagnostic and prognostic biomarker in esophageal squamous cell carcinoma
- Preoperative Zinc Deficiency as a Novel Prognostic Predictor for Postoperative Recurrence in Hepatocellular Carcinoma
BibTeX
@article{liu2026stk36,
title = {{STK36: a potential prognostic biomarker in hepatocellular carcinoma}},
author = {Ting Liu and Yanyong Ma and Zhizhao Li and Xuan Zhou},
journal = {BMC Cancer},
year = {2026},
month = aug,
doi = {10.1186/s12885-026-16691-y},
url = {https://doi.org/10.1186/s12885-026-16691-y},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - STK36: a potential prognostic biomarker in hepatocellular carcinoma
AU - Ting Liu
AU - Yanyong Ma
AU - Zhizhao Li
AU - Xuan Zhou
PY - 2026
DA - 2026/08/10
JO - BMC Cancer
DO - 10.1186/s12885-026-16691-y
UR - https://doi.org/10.1186/s12885-026-16691-y
AB - Background: STK36, a member of the serine/threonine kinase family, has been reported to be highly expressed in cancers. However, there have been fewer reports on the expression and role of STK36 in hepatocellular carcinoma (HCC). Methods: We used the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases to evaluate the differential expression of STK36 in HCC and normal tissues. Immunohistochemistry (IHC) and quantitative real-time reverse transcription polymerase chain reaction(qRT-PCR) validated the expression of STK36 in HCC. The chi-square test was employed to study the relationship between STK36 and clinical characteristics. The prognostic significance of STK36 expression was analyzed using Kaplan-Meier and Cox regression methods. We also studied the association between STK36 and immunity. We discussed STK36 expression at the single-cell and spatial transcriptome distribution levels. Drug sensitivity analysis was utilized to discuss the link between STK36 expression and small-molecule drugs. Gene Set Enrichment Analysis (GSEA) was used to discuss the function of STK36 in HCC. Results: STK36 expression was elevated in HCC from the TCGA and ICGC databases. IHC and qRT-PCR confirmed the overexpression of STK36 in HCC. STK36 expression had a positive correlation with T stage (tumor stage). STK36 expression was an independent prognostic factor affecting HCC patients’ outcomes. A relationship existed between STK36 expression and the infiltration of immune cells as well as immune checkpoints. Single-cell and spatial transcriptome analyses demonstrated that STK36 was upregulated in HCC. GSEA showed that STK36 was involved in some pathways, including ECM-receptor interaction, cell cycle, etc. Conclusion: STK36 acts as a potential prognostic index in HCC, serves as a potential biomarker for predicting response to immunotherapy, and provides a rationale for further functional studies.
SN - 1471-2407
ER -